Key result
New oral anticoagulants, including factor Xa and direct thrombin inhibitors, offer a more predictable anticoagulant effect than vitamin K antagonists without the need for routine monitoring.
Why the study?
Do new oral anticoagulants (factor Xa inhibitors and direct thrombin inhibitors) safely and effectively prevent stroke in patients with atrial fibrillation compared to vitamin K antagonists?
Do new oral anticoagulants (factor Xa inhibitors and direct thrombin inhibitors) safely and effectively prevent stroke in patients with atrial fibrillation compared to vitamin K antagonists?
New oral anticoagulants offer a more predictable effect without the need for routine monitoring compared to VKAs, though further issues must be addressed before widespread replacement.
May simplify AF anticoagulation; leaves open long-term safety and cost data before broad adoption.
Summary For decades vitamin K antagonists (VKA) have been the mainstay of treatment and prophylaxis of thromboembolism, in particular in primary prevention of systemic embolism associated with atrial fibrillation. Despite their efficacy, the use of VKA is associated with several limitations, including a narrow therapeutic window and a wide variability in the anticoagulant effect due to several drug-food and drug-drug interactions of VKA. The several limitations of VKA have resulted in their underuse for prevention of thromboembolic complications in patients with atrial fibrillation. Recently, new classes of oral anticoagulants have emerged: factor Xa (FXa) inhibitors and direct thrombin inhibitors. These new anticoagulants have a more predictable effect and eliminate the need for routine monitoring. Even though recent clinical trials have demonstrated the safety and efficacy of the new compounds, several unanswered issues must be addressed before conclusions can be drawn towards their potential to replace VKA.
No takes yet. Share an insight, caveat, or question.
A 2013 study conducted a review in Atrial fibrillation. New oral anticoagulants (factor Xa inhibitors and direct thrombin inhibitors) vs. Vitamin K antagonists (VKA) was evaluated on Prevention of thromboembolism and systemic embolism. New oral anticoagulants, including factor Xa and direct thrombin inhibitors, offer a more predictable anticoagulant effect than vitamin K antagonists without the need for routine monitoring.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: